He is Professor of Internal Medicine and Infectious Diseases at the Medical School of the National and Kapodistrian University of Athens and director of the MSc program of Infectious Diseases at the University of Athens. His main research contribution is immunomodulation in sepsis and in auto-inflammatory disorders. He has 571 publications in international peer-reviewed journals with more than 42,000 citations and h-index 94. He has contributed in the development of clarithromycin for immunomodulatory treatment of severe infections and in the recognition of hidradenitis suppurativa (HS) as an auto-inflammatory disorder and in the licensing of adalimumab for HS treatment. He is the current chairman of the European Sepsis Alliance and the current President of the Hellenic Society of Chemotherapy. His main achievement is the approval of anakinra for COVID-19 pneumonia in adults by the European Medicines Agency and the Food and Drug Administration through the phase 2 and 3 trials SAVE and SAVE-MORE that he designed and conducted.